Regeneron
As of the edition of 20 October 2026, Regeneron runs 85 drugs, 14 of them marketed; it is on route A at 11 targets and on route B at 7 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 4 company names in this family.
- Decibel Therapeutics: acquired in 2023; successor Regeneron Pharmaceuticals, Inc.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 14 |
| Active | 37 |
| Went quiet | 8 |
| Stopped | 19 |
| Status not established | 7 |
| Total | 85 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Aflibercept | Ends 2030 (orphan exclusivity) | 4 |
| Dupilumab | Ends 2031 (orphan exclusivity) | 1 |
| Cemiplimab | Ends 2030 (computed from the first US licence) | 2 |
| Alirocumab | Ends 2028 (orphan exclusivity) | 2 |
| Sarilumab | Ends 2029 (computed from the first US licence) | 1 |
| Linvoseltamab | Ends 2037 (computed from the first US licence) | 1 |
| Pozelimab | Ends 2035 (computed from the first US licence) | 1 |
| Rilonacept | Ends 2028 (orphan exclusivity) | 1 |
| Casirivimab | none listed | 0 |
| Odronextamab | none listed | 1 |
| Evinacumab | Ends 2033 (computed from the first US licence) | 2 |
| Imdevimab | none listed | 0 |
| Garetosmab | Ends 2038 (computed from the first US licence) | 1 |
| Atoltivimab | Ends 2032 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 11 targets, route B at 7 targets.
All 18 rows on route A or B
In the product18 company-target rows on route A or B; 15 are not shown here, and no score is.
See all 18 targets where Regeneron needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 77 trials led
- Immune system: 70 trials led
- Skin and connective tissue: 49 trials led